Multiple myeloma Cancer Multiple myeloma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. A diagnosis of smouldering multiple myeloma who have not received any treatment. 2. A diagnosis of multiple myeloma who have either: completed their first cycle of induction therapy, or are in remission following a successful haematopoietic stem cell transplant. 3. Aged 18 years or over.
Exclusion criteria
Exclusion criteria: 1. World Health Organisation (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status >1. 2. Deemed unsafe to exercise according to the Physical Activity Readiness Questionnaire (PARQ). 3. Any comorbidity that is likely to progress or be exacerbated over the course of the trial period. 4. Cognitive impairment deemed a risk by the healthcare team or participation in the trials (e.g. diagnosis of neurodegenerative disease). 5. Unable to understand explanations and/or provide informed consent. 6. Any condition and/or behaviour that would pose undue personal risk or introduce bias into the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The frequency of NK cells, T cells and monocytes in the blood will be measured using flow cytometry before exercise, immediately after exercise, and 30-minutes after exercise. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The frequency of polyclonal and clonotypic B cells will be measured using flow cytometry before exercise, immediately after exercise, and 30-minutes after exercise. 2. The cytotoxicity of NK cells will be measured using ex vivo assay models before exercise, immediately after exercise, and 30-minutes after exercise. 3. The efficacy of anti-myeloma therapies against a myeloma tumour cell line will be measured using ex vivo assay models before exercise, immediately after exercise, and 30-minutes after exercise. | — |
Countries
England, United Kingdom